712 North Inc. Highlights Novel OMA1 Screening Approaches in New Publication

Written By Marcel Alavi

January 13, 2022 — 712 North Inc., a pre-clinical pharmaceutical company specializing in mitochondrial medicine, announced today the publication of a comprehensive review article entitled “Recent advances in, and challenges of, designing OMA1 drug screens” in the peer-reviewed journal Pharmacological Research.

“While many have tried, few have succeeded,” said Dr. Marcel V. Alavi, CEO of 712 North. “Developing effective screening assays for the OMA1 protease is a critical prerequisite for unlocking new treatments for mitochondrial-driven diseases.”

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.

Marcel Alavi
Previous

712 North Inc. Announces USPTO Grant of New Patent for Innovative OMA1 Protease Modulators
Next

712 North Inc. Announces Landmark Publication of OMA1 High-Throughput Screening Platform